Scotland community wellness song UPS performer singer Inside Scotland

Del Amitri rocker Justin Currie opens up on Parkinson's battle and nickname he has given brutal disease

Reading now: 952
www.dailyrecord.co.uk

Scottish rock star Justin Currie has told how he is battling Parkinson’s disease - and he has nicknamed the illness Gavin.The Del Amitri frontman, 59, has been secretly living with the condition after being diagnosed in 2022.He says he first realised something was wrong when he found himself unable to hold a plectrum while playing guitar.Currie visited a neurologist at the Queen Elizabeth University Hospital where he received an unofficial diagnosis almost immediately.

After he was instructed to relax his arms then raise his arms above his head, the neurologist identified a trembling hand as a potential indicator of Parkinson’s, but it would be 12 months before the diagnosis was confirmed, leading to what the singer describes as “a year of dread and hope”.He said: “Twelve months later, I sail out of the same clinic secure in the knowledge that I’m ill and emboldened by the pleasant surprise that they have pills for this sort of thing.“I decide that I’m going to keep working, keep touring and keep playing, despite the uneasy feeling that another man is growing inside me, slowly seizing the means of control.“It’s definitely a fight to figure out who is in control. “You do think ‘who is in charge here?’ When you start losing control of something, even in a mild way, you feel and fear the encroachment of that thing inside you that is taking you over.

That’s what it feels like – a shadow inside you that is slowly but surely taking you over.”He added: “The shake in my hand I call Gavin, a traitor who comes and goes and betrays any surge of adrenalin, any passing thought, like a shadow who suddenly appears as a mocking fool parodying emotions, putting secret desires on public display.“Gavin every now and then appears...

Read more on dailyrecord.co.uk
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

Flu and COVID-19 surveillance report published - gov.uk
gov.uk
70%
479
Flu and COVID-19 surveillance report published
.COVID-19 activity remained stable.SARS-CoV-2 positivity remained stable at 3.7% in week 11 compared to 3.7% in the previous week. This is based on a percentage of people who test positive among those with symptoms tested at sentinel “spotter” laboratories, reported through the Respiratory DataMart surveillance system.COVID-19 case rates and positivity in Pillar 1 decreased overall and within some age, ethnic groups, and regions in week 11.Through the SIREN healthcare cohort study, the SARS-CoV-2 positivity increased in week 11 compared to the previous week.COVID-19 hospitalisations increased slightly to 1.85 per 100,000 compared to 1.76 per 100,000 in the previous week.COVID-19 ICU admissions remained low and stable at 0.06 per 100,000 in week 11.The total number of confirmed COVID-19 acute respiratory incidents decreased compared to the previous week, with 5 incidents reported in England during week 11.The highest hospital admission rate is currently in the North East at 3.44 per 100,000.Those aged 85 years and over had the highest hospital admission rate, which increased to 21.45 per 100,000, with most of the remaining age groups remaining stable.Details of the Spring 2024 COVID-19 vaccination programme will be confirmed soon by NHS England, which will be offered to those who are aged 75 years and over, residents in a care home for older adults and individuals aged 6 months and over who are immunosuppressed.Influenza activity remained stable.Influenza positivity increased slightly to 5.9% in week 11 compared to 5.3% in the previous week.
Clinical platform trials for coronavirus (COVID-19) treatments - gov.uk - Britain
gov.uk
79%
425
Clinical platform trials for coronavirus (COVID-19) treatments
, the COVID-19 Antivirals and Therapeutics Taskforce closed on 31 March 2023.Find out more about on the National Institute for Health and Care Research (NIHR) website.Find out more about on the NHS website.Clinical trials are essential to finding new and improved methods of treating different diseases including coronavirus (COVID-19).Clinical trials allow us to understand whether new treatments:Phase 1 and 2 trials are early-stage trials involving small numbers of participants to ensure a treatment is safe to use and shows evidence of a benefit beyond the standard of care.Treatments that are found to be safe at this stage may then proceed to be tested in a phase 3 clinical trial.Phase 3 trials involve large numbers of patients and assess whether a treatment is effective enough to be used more widely in the NHS.The National Institute for Health and Care Research (NIHR) established a single UK-wide process to prioritise COVID-19 research as Urgent Public Health research early in the COVID-19 pandemic. The purpose was to:The COVID-19 Antivirals and Therapeutics Taskforce worked with NIHR and other partners to horizon scan and monitor national and international developments in COVID-19 antivirals and therapeutics.The Department of Health and Social Care (DHSC) is continuing to support a series of national clinical trial ‘platforms’ across all phases of human trials and in a range of patient cohorts.
DMCA